The team turned to the SAMP8 mouse, a well-established model of accelerated aging that develops learning and memory deficits as early as four months of age and, from six months onward, begins to display neuropathological hallmarks reminiscent of Alzheimer’s disease. Within the hippocampus—the brain’s memory hub—these mice undergo a characteristic sequence: an early burst of neurogenic activity in the dentate gyrus, the region where new neurons are born, followed by depletion of the resident neural stem cell pool. That exhaustion, driven by signals within the local neurogenic niche, makes the SAMP8 an ideal testing ground for interventions meant to preserve or restore the birth of new neurons in adulthood.

The compound under scrutiny, known as ER272 or DPB, is a 12-deoxyphorbol diterpene originally isolated from plants of the Euphorbia genus. Unlike some of its chemical relatives, it does not promote tumors; instead, it activates classical protein kinase C isoforms by binding their C1B regulatory domain. Previous work had shown that ER272 triggers the release of TGF-α and exerts both neurogenic and neuroprotective effects, and that a two-month treatment ameliorated cognitive decline in six-month-old male SAMP8 mice. What remained unknown was whether females would respond at all—a question that matters, because most preclinical studies of hippocampal neurogenesis have been conducted in males alone, or in mixed cohorts never analyzed by sex.

To find out, the researchers gave four-month-old male and female SAMP8 mice daily intranasal doses of ER272 for eight consecutive weeks, delivering 18 microliters of a one-micromolar solution in alternating aliquots to each nostril. Age-matched SAMR1 mice, a strain that ages normally, served as controls. Throughout the treatment period, every animal received injections of BrdU, a synthetic nucleoside that incorporates into the DNA of dividing cells, allowing the team to tag and later count every neuron and glial cell born during the experiment. Behavioral testing—open field, new object discrimination, and the Morris water maze—took place during the final two weeks, with investigators blinded to treatment assignment.

The behavioral results were unambiguous. Both male and female SAMP8 mice showed impaired spatial learning in the water maze and severely compromised episodic memory in the new object discrimination task, particularly on the “what” and “when” components that test whether an animal remembers which object it saw and when. Yet only the males benefited from the drug. Treated males spent significantly more time in the target quadrant during the water maze retention probe and fully recovered their episodic memory performance. Treated females showed only a slight, statistically insignificant improvement, and direct comparisons confirmed that ER272-treated females performed significantly worse than treated males on the “what” and “when” paradigms. Open field testing ruled out changes in general locomotor activity as an explanation.

Underlying those divergent behavioral outcomes lay equally divergent cellular pictures. In male SAMP8 mice, the number of BrdU-labeled proliferating cells in the dentate gyrus dropped, and the population of newly generated immature neurons—cells positive for both BrdU and doublecortin—fell significantly, a loss that ER272 treatment fully prevented. In treated males, BrdU-positive cell counts even exceeded those of normal-aging controls and reached roughly double the levels seen in treated females. Female SAMP8 mice, by contrast, showed no significant reduction in newly generated immature neurons compared with female controls, and the drug produced only a modest, non-significant uptick. Notably, the proportion of dividing cells that adopted a neuronal fate stayed constant across groups, suggesting the drug acts on the size of the proliferative pool rather than on cell fate decisions themselves.

Three-dimensional reconstructions of individual immature neurons deepened the contrast. In male SAMP8 mice, the dendritic trees of doublecortin-positive cells were stunted: total dendritic length, dendritic surface area, segment counts, and terminal branch numbers were all reduced relative to controls, and Sholl analysis revealed fewer intersections at 60 to 70 micrometers from the cell body. ER272 reversed every one of these morphological deficits in males. Female SAMP8 mice displayed none of these abnormalities to begin with, and the treatment had no measurable effect on their neuronal architecture. In parallel, the team documented a four-fold surge in newly generated astrocytes—S100β-positive cells born during the treatment window—in male SAMP8 mice, reflecting the age-related shift of neural stem cells toward glial rather than neuronal commitment. The drug blocked that surge in males; females, whose astrocyte numbers were roughly half those of males throughout, showed no such shift and no drug response.

Analysis of the stem cell reservoir itself completed the picture. Both sexes of SAMP8 mice carried a reduced pool of radial glia-like neural stem cells, marked by GFAP and SOX2 expression. But when the researchers used MCM2, a component of the DNA replication licensing machinery, to identify stem cells that had re-entered the cell cycle, a sex split emerged: male SAMP8 mice showed a doubled proportion of activated stem cells, which treatment pushed to three times control levels, while females showed no change. The authors suggest that males may retain a larger reserve of resting, non-dormant stem cells capable of re-entering the cell cycle when stimulated, whereas females may simply have less baseline neurogenic activity to modulate—or may be at a different stage of pathological progression at six months of age.

Perhaps the most consequential finding concerns how the data are aggregated. When the researchers pooled males and females, the combined results closely mirrored the male phenotype across nearly every measure—new neurons, mature neurons, astrocytes, stem cell activation, and cognition—effectively erasing the female-specific patterns entirely. This male-driven bias in mixed-sex analyses has been documented in other preclinical fields, but seeing it play out across an entire neurogenic aging study is a stark demonstration of why the practice persists as a blind spot. Had the team analyzed only combined cohorts, the female data would have been invisible, and the conclusion would have been that the drug works uniformly.

The authors caution that several questions remain open. The estrous cycle was not monitored, though the two-month treatment spanned multiple cycles, making transient hormonal fluctuations an unlikely driver of the directional differences observed. Biodistribution of intranasally delivered ER272 was not directly tracked, so whether the compound acts directly on the hippocampus or through broader central signaling remains unresolved, and pulse-chase designs will be needed to separate effects on proliferation, survival, and lineage progression. Sex hormones, particularly estrogens, are known to modulate stem cell proliferation and neuronal survival and may contribute to the divergent trajectories. What the study establishes firmly is that male and female brains do not simply age at different speeds along a single path—they appear to follow distinct neurogenic aging trajectories altogether. For a field racing to develop therapies that boost adult neurogenesis against dementia, that distinction may determine which patients a treatment can actually help.

Subject of Research: Sex differences in hippocampal neurogenesis and cognitive response to diterpene treatment in a mouse model of accelerated aging

Article Title: Sex‐Specific Neurogenic and Cognitive Responses in a Murine Model of Accelerated Aging

Article References: Gómez‐Oliva, R., Chamorro‐Francisco, A., Atienza‐Navarro, I., Carrascal, L., Freire‐Aragón, M. D., Hernández‐Galán, R., Nunez‐Abades, P., García‐Alloza, M., & Castro, C. (2026). Sex‐Specific Neurogenic and Cognitive Responses in a Murine Model of Accelerated Aging. Aging Cell, 25(10), Article e70663. https://doi.org/10.1111/acel.70663

Image Credits: AI Generated

DOI: 10.1111/acel.70663

Keywords: hippocampal neurogenesis, aging, SAMP8 mice, sex differences, ER272, dentate gyrus, neural stem cells, cognitive decline, astrocytes, Morris water maze, protein kinase C, Alzheimer's disease

The material at the heart of the study, published in the journal Angiogenesis, is a polymer built from 2-methacryloyloxyethyl phosphorylcholine, abbreviated MPC, whose side chains carry the same phosphorylcholine head group that decorates the outer leaflet of every human cell membrane. Phosphorylcholine-based polymers have a long and distinguished history in biomedical engineering precisely because of this biomimicry. They are zwitterionic, meaning they carry paired positive and negative charges that produce a strongly hydrated surface, which resists protein adsorption, platelet adhesion, and thrombus formation. That property has made MPC polymers the coating of choice for cardiovascular stents, contact lenses, and other blood-contacting medical devices. What the Montreal team, led by co-senior authors May Griffith and Bruno Larrivée, has done is to flip the script on this famously inert material: instead of exploiting phosphorylcholine chemistry to keep cells at arm’s length, they deploy nanoparticles of the polymer as an active biological stimulus that vessel cells willingly devour.

The nanoparticles themselves are formed from polyMPC, the polymerized form of the methacrylated monomer, and were engineered to fall below a critical size threshold of roughly 150 nanometers in diameter. That figure is not arbitrary. Work on size-dependent cellular uptake stretching back to classic studies of clathrin- and caveolae-mediated endocytosis has shown that particles in this range are internalized by cells far more efficiently than larger counterparts, which tend to remain at the surface or enter through less productive pathways. When the researchers exposed human umbilical vein endothelial cells, the workhorse HUVEC model of vascular biology, to these sub-150-nanometer particles, the cells readily swallowed them. Once inside, the nanoparticles did something remarkable: rather than sitting inertly in endosomes, they triggered a cascade of signaling events that pushed the endothelial cells into an actively angiogenic state.

Tracing that cascade led the team to protein kinase C, or PKC, a family of enzymes that sits at a major signaling crossroads in many cell types. Upon internalization of the polyMPC nanoparticles, PKC was recruited to the plasma membrane, the canonical step that converts the kinase from an inactive cytosolic form into its active, membrane-bound state. PKC activation in endothelial cells is tightly linked to the stimulation of endothelial nitric oxide synthase, which produces nitric oxide, a master regulator of vessel dilation, endothelial migration, and new vessel sprouting. The finding that a synthetic zwitterionic polymer can engage this pathway offers a mechanistic explanation for how a material long considered biologically quiet can, in nanoparticle form, become a potent pro-angiogenic agent. It also suggests that the cell membrane itself, or the membrane trafficking machinery that processes the internalized particles, may be the unexpected trigger that converts a physical delivery event into a biochemical signal.

The downstream consequences of this activation were mapped with RNA sequencing, an unbiased technique that captures the full transcriptional response of treated cells. The profiles of HUVECs exposed to polyMPC nanoparticles showed upregulation of pro-angiogenic growth factors, including VEGF and fibroblast growth factor 2 (FGF2), two of the most important drivers of blood vessel growth in both development and repair. In other words, the nanoparticles did not act as growth factors themselves; they acted upstream, flipping genetic switches inside endothelial cells so that the cells became factories for their own angiogenic signals. Functional assays confirmed the transcriptional story: treated endothelial cells proliferated more vigorously and mounted characteristic angiogenic responses in culture, forming the tube-like networks that are the in vitro hallmark of vessel-forming behavior.

Crucially, the pro-angiogenic effect was not confined to a single cell type. The researchers found that polyMPC nanoparticles also promoted the expansion of endothelial progenitor cells derived from human cord blood and bone marrow. These progenitors are the circulating seed cells that the body uses to repair and rebuild vasculature, and their mobilization and expansion are central goals of cell-based approaches to ischemic disease. A material that can simultaneously stimulate mature endothelial cells and support the growth of progenitor populations could therefore act on both arms of vascular regeneration, the local sprouting of new vessels from existing ones and the recruitment of the cellular precursors that seed new vascular networks.

To test whether the effect would survive the far messier environment of living tissue, the team implanted polyMPC nanoparticles inside Matrigel plugs under the skin of mice, a standard in vivo assay in which a basement-membrane extract serves as a neutral scaffold. Blood vessels from the surrounding host tissue grow into the plug only if something inside it attracts them, so the degree of vascularization provides a direct readout of pro-angiogenic activity. The polyMPC-laden plugs produced a significant angiogenic response, drawing in host vessels at levels that confirmed the cell culture results translated to a living organism. Equally important was a observation about persistence: the delivered nanoparticles could be retained in tissue for extended periods, which means a single implantation could provide a sustained stimulus rather than the brief pulse of activity that plagues injected protein therapeutics. Because the nanoparticles work by inducing the tissue’s own production of VEGF, FGF2, and other growth factors, the therapeutic signal is continuously renewed at the site where it is needed, in the correct proportions and in the natural context of the tissue microenvironment.

The clinical problem the researchers are aiming at is enormous. Ischemic vascular pathologies, including peripheral artery disease, critical limb ischemia, and myocardial infarction, affect hundreds of millions of people worldwide and are a leading cause of amputation and heart failure. Existing attempts at therapeutic angiogenesis have ranged from gene therapy delivering VEGF or hepatocyte growth factor genes to infusions of autologous stem cells, with mixed and often underwhelming results in controlled trials. Recombinant protein approaches face pharmacological hurdles: free growth factors have short half-lives, risk ectopic vessel growth and leaky, malformed vasculature, and are costly to produce in pharmaceutical grade. The polyMPC strategy sidesteps several of these objections at once. The particles are made from a polymer with an established safety record in approved medical devices, they are relatively inexpensive to synthesize compared with recombinant proteins or viral vectors, and their mechanism recruits the body’s own regulated programs of vessel growth rather than flooding tissue with a single supraphysiological factor.

There are also broader implications for the field of biomaterials science. Phosphorylcholine polymers have been celebrated for four decades as the archetypal non-fouling, non-activating surface chemistry, and their zwitterionic cousins are now being engineered into next-generation lipid nanoparticles for drug and RNA delivery, where their ability to modulate interactions with lipid rafts and membrane trafficking pathways is increasingly recognized. The Montreal study adds a new chapter to that story by showing that the same membrane-mimetic chemistry, presented in the right physical form and size range, can be an active participant in cell signaling rather than a passive bystander. The boundary between a biomaterial that hides from biology and one that directs biology may be thinner than the field has assumed, and size, presentation, and cell type all appear to determine which side of that boundary a given formulation occupies.

The work remains at the preclinical stage, and the path from subcutaneous Matrigel plugs in mice to treating a diabetic patient’s ischemic foot is long and demanding, requiring tests of dose, delivery route, long-term biocompatibility, and efficacy in models of true tissue ischemia. The authors have filed a provisional patent application through their hospital research centre, a signal that they see a translational pathway for the technology. Even at this early stage, the concept is striking: a cheap, stable, biocompatible polymer particle that quietly enters blood vessel cells, wakes up their internal growth programs, and leaves the tissue to heal itself with vessels built from its own blueprint. If that concept survives the gauntlet of preclinical and clinical testing, phosphorylcholine, one of the most familiar molecules in biomaterials science, may find its most consequential role not in coating devices, but in regrowing the vasculature that failing tissues so desperately need.

Subject of Research: Polymer nanoparticles that stimulate angiogenesis in ischemic tissue

Article Title: Angiogenesis-promoting properties of phosphorylcholine mimetic nanoparticles

Article References: Moradi, M., Poudel, B. K., Hooker, E., Aghajanzadeh-Kiyaseh, M., Rusu, D., Griffith, M., & Larrivée, B. (2026). Angiogenesis-promoting properties of phosphorylcholine mimetic nanoparticles. Angiogenesis, 29(4), Article 71. https://doi.org/10.1007/s10456-026-10094-0

Image Credits: AI Generated

DOI: 10.1007/s10456-026-10094-0

Keywords: angiogenesis, nanoparticles, polyMPC, phosphorylcholine, therapeutic angiogenesis, endothelial cells, protein kinase C, VEGF, FGF2, endothelial progenitor cells, RNA sequencing, ischemic disease